Cytoplasts and Mo1-deficient neutrophils pretreated with plasma and LPS induce lung injury.
We hypothesized that neutrophil adhesion and lung injury could occur independent of the surface receptor glycoprotein, Mo1 (C3bi receptor). We investigated whether preincubation of human neutrophil-derived cytoplasts (cell fragments that lack nuclei and granules and have a fixed number of surface Mo1 receptors) with plasma and lipopolysaccharide (LPS) would augment the cytoplasts' ability to cause lung injury when activated. We also investigated whether preincubating normal human neutrophils treated with anti-Mo1 antibody with plasma and LPS would increase the neutrophils' ability to adhere and cause lung injury. Human neutrophils infused into isolated salt-perfused rat lungs subsequently stimulated with phorbol 12-myristate 13-acetate (PMA) resulted in lung injury as assessed by the accumulation of 125I-bovine serum albumin in the lung parenchyma. The infusion of cytoplasts resulted in significantly less injury. Cytoplasts preincubated in 20% human plasma and LPS caused an increase in lung injury. Similarly, neutrophils treated with plasma, LPS, and anti-Mo1 antibody or neutrophils congenitally deficient in the Mo1 surface receptor and treated with plasma and LPS augmented lung injury. Plasma and LPS preincubation also increased anti-Mo1 antibody-treated neutrophil adhesion to endothelial cell monolayers after activation by PMA. Thus, plasma and LPS increase adhesion and lung injury caused by neutrophils or neutrophil fragments that share defects in Mo1 receptor expression.
Wencel
M L
ML
Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor 48109.
Morganroth
M L
ML
Schoeneich
S O
SO
Gannon
D E
DE
Varani
J
J
Todd
R F
RF
Ryan
U S
US
Boxer
L A
LA
D000818:Animals; D002462:Cell Membrane / Q000502:physiology; D003574:Cytochrome c Group / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000633:toxicity*; D008168:Lung / Q000187:drug effects / Q000473:pathology* / Q000502:physiology; D009504:Neutrophils / Q000502:physiology*; D010477:Perfusion; D051381:Rats; D011951:Receptors, Complement / Q000235:genetics / Q000502:physiology*; D017463:Receptors, Complement 3b; D013481:Superoxides / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D003574:Cytochrome c Group; D008070:Lipopolysaccharides; D011951:Receptors, Complement; D017463:Receptors, Complement 3b; D013481:Superoxides; D013755:Tetradecanoylphorbol Acetate